Mini-PBPK-Based Population Model and Covariate Analysis to Assess the Complex Pharmacokinetics and Pharmacodynamics of RO7449135, an Anti-KLK5/KLK7 Bispecific Antibody in Cynomolgus Monkeys-Reference-Cited by-同舟云学术

Mini-PBPK-Based Population Model and Covariate Analysis to Assess the Complex Pharmacokinetics and Pharmacodynamics of RO7449135, an Anti-KLK5/KLK7 Bispecific Antibody in Cynomolgus Monkeys

Published:2023-06-23 Issue:4 Volume:25 Page:
ISSN:1550-7416
Container-title:The AAPS Journal
language:en
Short-container-title:AAPS J

Author:

Cai Hao,Tao Xun,Shim Jeongsup,Bauer Rebecca N.,Bremer Meire,Bu Wei,LaMar Jason,Basile Rachel,Dere Edward,Nguyen Tien,Laing Steven,Chan Pamela,Yi Tangsheng,Koerber James T.,Sperinde Gizette,Stefanich Eric

Publisher

Springer Science and Business Media LLC

Subject

Pharmaceutical Science

Link

https://link.springer.com/content/pdf/10.1208/s12248-023-00829-y.pdf

Reference30 articles.

1. Chavanas S, et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet. 2000;25(2):141–2.

2. Sarri CA, et al. Netherton syndrome: a genotype-phenotype review. Mol Diagn Ther. 2017;21:137–52.

3. Descargues P, et al. Corneodesmosomal cadherins are preferential targets of stratum corneum trypsin-and chymotrypsin-like hyperactivity in Netherton syndrome. J Investig Dermatol. 2006;126(7):1622–32.

4. Furio L, Hovnanian A. Netherton syndrome: defective kallikrein inhibition in the skin leads to skin inflammation and allergy. Biol Chem. 2014;395(9):945–58.

5. de Veer SJ, et al. Proteases: common culprits in human skin disorders. Trends Mol Med. 2014;20(3):166–78.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A generic anti-drug antibody assay for monoclonal antibody therapeutics with broad dynamic range eliminates the need for titer evaluation in preclinical studies;Journal of Pharmaceutical and Biomedical Analysis;2024-10

2. Sialic Acid Mediated Endothelial and Hepatic Uptake: A Mechanism based Mathematic Model Elucidating the Complex Pharmacokinetics and Pharmacodynamics of Efmarodocokin Alfa, a Variably Glycosylated Fusion Protein;Journal of Pharmaceutical Sciences;2024-03

3. Overcoming Soluble Target Interference in Measurement of Total Bispecific Therapeutic Antibody Concentrations;The AAPS Journal;2023-08-18

4. Αnti-KLK5/KLK7 Antibody-based Strategies for the Treatment of Epidermal Diseases;Current Pharmaceutical Design;2023-08